Skip to main content

Advertisement

SpringerLink
Log in

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SCH 66336 when administered with temozolomide to adults with malignant glioma previously treated with radiation therapy. Patients were enrolled to two strata: stratum A, patients not on enzyme-inducing antiepileptic drugs (EIAEDs); stratum B, patients receiving EIAEDs. Temozolomide was administered at a dose of 150 mg/m2 daily for five days for the first 28-day cycle and escalated to 200 mg/m2, during subsequent cycles. SCH 66336 was administered twice daily on a continuous daily dosing schedule. The starting dose of SCH 66336 was 75 mg twice daily for stratum A and 125 mg twice daily for stratum B. Cohorts of 3–6 patients were treated per dose level until DLT was observed. Thirty six patients were enrolled on study, including 21 patients on stratum A and 15 on stratum B. All DLTs were grade 3 events and included hepatic, gastrointestinal, renal, thrombotic and constitutional events. No grade 4 or 5 toxicities were observed. The phase II dose of SCH 66336 when combined with temozolomide is 150 mg twice daily for patients not on EIAEDs and 175 mg twice daily for patients on EIAEDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  2. Louis D, Cavenee W (2001) Molecular biology of central nervous system neopolasms. In: De Vita V, Hellman S, Rosenberg S (eds) Principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2091–2100

    Google Scholar 

  3. Mischel PS, Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13:52–61

    Article  PubMed  Google Scholar 

  4. Guha A (1998) Ras activation in astrocytomas and neurofibromas. Can J Neurol Sci 25:267–281

    PubMed  CAS  Google Scholar 

  5. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689

    PubMed  CAS  Google Scholar 

  6. Tuzi NL, Venter DJ, Kumar S, Staddon SL, Lemoine NR, Gullick WJ (1991) Expression of growth factor receptors in human brain tumours. Br J Cancer 63:227–233

    Article  PubMed  CAS  Google Scholar 

  7. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A (1999) Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45:1442–1453

    Article  PubMed  CAS  Google Scholar 

  8. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A (1999) Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by ras. Int J Cancer 81:118–124

    Article  PubMed  CAS  Google Scholar 

  9. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A (1997) Proliferation of human malignant astrocytomas is dependent on ras activation. Oncogene 15:2755–2765

    Article  PubMed  CAS  Google Scholar 

  10. Feldkamp MM, Lau N, Guha A (1999) Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18:7514–7526

    Article  PubMed  CAS  Google Scholar 

  11. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 280:31101–31108

    Article  PubMed  CAS  Google Scholar 

  12. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7:1438–1445

    PubMed  CAS  Google Scholar 

  13. Smalley KS, Eisen TG (2003) Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165–175

    Article  PubMed  CAS  Google Scholar 

  14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  15. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63:5656–5668

    PubMed  CAS  Google Scholar 

  16. Chow LQ, Eckhardt SG, O’Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L (2008) A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 62:631–646

    Article  PubMed  CAS  Google Scholar 

  17. Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM (2007) Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 13:576–583

    Article  PubMed  CAS  Google Scholar 

  18. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK (2004) Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10:2968–2976

    Article  PubMed  CAS  Google Scholar 

  19. Cortes J, Jabbour E, Daley GQ, O’Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H (2007) Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110:1295–1302

    Article  PubMed  CAS  Google Scholar 

  20. Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI (2011) Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:455–463

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, 27710, USA

    Annick Desjardins, David A. Reardon, Katherine B. Peters, Stevie Threatt, Allan H. Friedman, Henry S. Friedman & James J. Vredenburgh

  2. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, 27710, USA

    April D. Coan & James E. Herndon II

Authors
  1. Annick Desjardins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine B. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stevie Threatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. April D. Coan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James E. Herndon II
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Allan H. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henry S. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. James J. Vredenburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annick Desjardins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desjardins, A., Reardon, D.A., Peters, K.B. et al. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol 105, 601–606 (2011). https://doi.org/10.1007/s11060-011-0627-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0627-0

Keywords

Search

Navigation